Wire · opportunities
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The FDA approved UX111 (Fayuvi), the first gene therapy for pediatric Sanfilippo syndrome type A, under an accelerated approval pathway based on biomarker and neurodevelopmental outcomes from the Transpher A clinical program and long-term follow-up data. The one-time intravenous AAV9 therapy showed sustained reduction in cerebrospinal fluid heparan sulfate and developmental gains in treated children.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 17 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
You must prepare for an emerging market in ultra-rare pediatric neurodegenerative diseases as gene therapy approvals like UX111 open regulatory doors and raise investor attention to these conditions. Focus your products or pipelines on rapid clinical readouts and biomarker-driven approvals to align with evolving FDA strategies.
◆ Coverage
9 sources · first reported 17 Sep 2026 · latest 28 Sep 2026
◆ Related on Wire
◆ Topics